The National Lipid Association (NLA) is an American non-profit multidisciplinary medical society that aims to enhance the practice of lipid management in clinical medicine. The NLA focuses on the prevention of cardiovascular disease and other lipid-related disorders.[1]
Overview
The National Lipid Association was formed in 1997 and has over 2,000 members.[2][3] It provides medical education for healthcare professionals and physicians to advance knowledge and certification in clinical lipidology.[2] Joseph Saseen is the current president of NLA.[4][5] In 2014, the NLA proposed a working definition of statin intolerance and made general recommendations for health professionals.[6][7]
The NLA publishes the Journal of Clinical Lipidology.[8]
Scientific statements
In 2019, the NLA's Nutrition and Lifestyle Task Force published a scientific statement based on a comprehensive review of recent clinical evidence on the effects of low and very-low-carbohydrate diets on the management of body weight and other cardiometabolic risk factors.[9][10] The statement concluded that low and very-low-carbohydrate die are not superior to other dietary approaches for weight loss and are difficult to maintain in the long term.[9][10]
In 2021, the NLA published a scientific statement on lipid measurements in the management of cardiovascular diseases.[11]
In 2022, the NLA published an official scientific statement on statin intolerance, updating the definition which now classifies statin intolerance as either partial or complete.[12] The 2022 statement recommends different strategies to help patients stay on statin medications, and alternative medications to those who cannot tolerate statins.[1][13]
Selected publications
- Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA, Dixon DL, Maki KC (2022). "NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient". J Clin Lipidol. 16 (4): 361–375. doi:10.1016/j.jacl.2022.05.068. PMID 35718660. S2CID 249868408.
{{cite journal}}
: CS1 maint: multiple names: authors list (link)
References
- 1 2 "Saseen Co-Authors National Lipid Association Official Scientific Statement on Statin Intolerance". news.cuanschutz.edu. Retrieved 9 January 2023.
- 1 2 "Who We Are". lipid.org. Retrieved 9 January 2023.
- ↑ "USA – National Lipid Association (NLA)". athero.org. Retrieved 9 January 2023.
- ↑ "The NLA Welcomes New Leadership". lipid.org. Retrieved 9 January 2023.
- ↑ "Professor Joseph Saseen named president of National Lipid Association". news.cuanschutz.edu. Retrieved 9 January 2023.
- ↑ Guyton JR, Bays HE, Grundy SM, Jacobson TA (2014). "The National Lipid Association Statin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014 update". J Clin Lipidol. 8 (3): 72–81. doi:10.1016/j.jacl.2014.03.002. PMID 24793444.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ↑ "The National Lipid Association Addresses the Safety of Statins and Provides Recommendations to Clinicians and Patients". businesswire.com. Retrieved 9 January 2023.
- ↑ "Journal of Clinical Lipidology". sciencedirect.com. Retrieved 9 January 2023.
- 1 2 Kirkpatrick CF, Bolick JP, Kris-Etherton PM, et al. (2019). "Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: A scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force". Journal of Clinical Lipidology. 13 (5): 689–711.e1. doi:10.1016/j.jacl.2019.08.003. PMID 31611148. S2CID 203514787.
- 1 2 "Low-carbohydrate diet claims scrutinized". quackwatch.org. Retrieved 9 January 2023.
- ↑ "Utilization of Clinical Testing in the Setting of Dyslipidemia". acc.org. Retrieved 9 January 2023.
- ↑ "NLA 2022 Definition of Statin Intolerance". acc.org. Retrieved 9 January 2023.
- ↑ "New National Lipid Association Statement on Statin Intolerance". medscape.com. Retrieved 9 January 2023.